FDA Considers Approval of Peptide Production, Regulatory Uncertainty Over Experimental Drugs in the U.S. At the end of July, peptide drugs, which are popular but still experimental, became the focal point of an extended hearing organized by the U.S. Food and Drug Administration (FDA) advisory panel. This panel reviewed and voted in favor of supporting the production of seven different peptide therapies, excluding only one, despite concerns raised even by FDA scientists themselves.
These peptides include some of the most popular ones such as BPC-150, TB-500, and MOTS-c. However, this recommendation does not necessarily mean a change in the legal status of these compounds. Currently, pharmacies in the U.S. are still prohibited from producing these peptides.
Approval Process and Legal Challenges
Following the hearing, FDA staff and officials will continue reviewing data to decide whether to allow U.S. pharmacies to manufacture any of the seven peptides mentioned by the advisory panel. According to Dr. Jessica Duncan, Medical Director of IVIM Health consulting firm, she has to explain to many patients about the complex and uncertain timeline for these therapies to reach the market.
"They are becoming increasingly curious. We can only state that the launch timing is still uncertain," said Ms. Duncan.
The approval rate for peptides is likely high when FDA usually follows recommendations from its advisory committees. Moreover, demand for these products is growing, and Health Secretary Robert F. Kennedy Jr. has also called for bringing them to market.










